

Special Issue

Tumor Microenvironment in Primary Liver Cancer

Message from the Guest Editors

Liver cancers, including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), remain a global health challenge and their incidence is growing worldwide. It is estimated that, by 2025, >1 million individuals will be affected by liver cancer annually. In HCC, TME consists of a mixture of three major players including normal, fibrotic and neoplastic areas accompanied by distinct distribution patterns of tumorous, stromal and immune cells, which are relevant to the clinical outcome of patients. In-depth analysis of the immune TME disclosed distinct subclasses of patients showing differences in clinical prognosis and response to personalized treatment. For this Special Issue of *Cancers*, we invite authors to submit contributions that will provide new insights into compositions and functions of the diverse cell types and their metabolomes, secretomes, exosomes, and other soluble factors, responsible for cancer heterogeneity and tumor evolution, in particular findings that could have a promising translational application.

Guest Editors

Dr. Stefania Mantovani

Division of Clinical Immunology and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy

Dr. Barbara Oliviero

Division of Clinical Immunology and Infectious Diseases, Fondazione IRCCS San Matteo, 27100 Pavia, Italy

Deadline for manuscript submissions

closed (28 June 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/127586

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)